Literature DB >> 9057798

Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?

K Maeda1, R Kimura, K Komuta, T Igarashi.   

Abstract

Polymyositis and dermatomyositis are inflammatory muscular diseases of unknown etiology which have interstitial pneumonitis as a serious complication. From 1987 to 1994, we used cyclosporine to treat 14 polymyositis/dermatomyositis patients (8 with and 6 without interstitial pneumonitis). In combination with prednisolone, cyclosporine was either added to or substituted for conventional cytotoxic drugs (azathioprine, cyclophosphamide and methotrexate). Cyclosporine was effective against both myositis and interstitial pneumonitis when used early in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057798     DOI: 10.3109/03009749709065660

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  13 in total

Review 1.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 2.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 3.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Armin Schnabel; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Treatment of refractory polymyositis and dermatomyositis.

Authors:  Steven R Ytterberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

5.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

6.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

7.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

Review 8.  Pulmonary complications of inflammatory myopathy.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

9.  Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.

Authors:  K Kurasawa; Y Nawata; K Takabayashi; K Kumano; Y Kita; Y Takiguchi; T Kuriyama; M Sueishi; Y Saito; I Iwamoto
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 10.  Lipid-lowering Therapies in Myositis.

Authors:  Marisa C Mizus; Eleni Tiniakou
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.